8-K: Orgenesis Acquires CAR-T Technology Assets from Broaden Bioscience in Multi-Million Dollar Deal

Orgenesis Inc. has acquired CAR-T cell therapy processing technology from Broaden Bioscience for a maximum of $11 million, offset by existing debt, and secured an exclusive cell therapy processing agreement.

Summary

• Orgenesis Inc. has entered into an Asset Purchase Agreement with Broaden Bioscience and Technology Corp. to acquire their CAR-T and RACE CAR-T cell therapy processing technology.
• The acquisition includes all related intellectual property, such as patents, know-how, and licenses.
• The purchase price is capped at $11 million, but will be reduced by a $10,767,298 debt that Broaden owes to Orgenesis.
• The remaining balance can be paid in Orgenesis stock at $3.00 per share or 10% above market price, whichever is higher, or through a 24-month amortizing note.
• Broaden will also exclusively purchase cell therapy processing services from Orgenesis Maryland LLC in perpetuity for the acquired assets.

Sentiment

Score: 7

Explanation: The acquisition is a positive step for Orgenesis, providing valuable technology and a recurring revenue stream. However, the potential for stock dilution and the uncertainty of the valuation temper the overall sentiment.

Positives

• Orgenesis gains valuable CAR-T and RACE CAR-T cell therapy processing technology.
• The acquisition includes all related intellectual property, strengthening Orgenesis's portfolio.
• The purchase price is offset by a significant debt owed by Broaden, reducing the cash outlay.
• The exclusive processing agreement with Broaden provides a recurring revenue stream for Orgenesis Maryland LLC.
• The deal consolidates the relationship between Orgenesis and Broaden.

Negatives

• The maximum purchase price of $11 million could be considered high if the third-party valuation is close to this amount.
• The payment in stock could dilute existing shareholders if the stock price is not significantly above $3.00 per share.
• The 24-month note payment option could add to Orgenesis's debt burden.
• The valuation of the assets is still pending and could impact the final purchase price.

Risks

• The third-party valuation could be lower than expected, impacting the final purchase price.
• The integration of the acquired technology may present challenges.
• The success of the acquired technology in the market is not guaranteed.
• The exclusive processing agreement with Broaden may not generate the expected revenue if Broaden's business does not perform well.

Future Outlook

Orgenesis will integrate the acquired technology and develop treatments for sale to third parties. The company will also benefit from the exclusive processing agreement with Broaden.

Industry Context

This acquisition reflects the growing interest in cell therapy and CAR-T technology within the biotechnology industry. It positions Orgenesis to expand its capabilities in this rapidly evolving field.

Comparison to Industry Standards

• The acquisition of CAR-T technology is a common strategy for companies looking to expand their presence in the cell therapy market, similar to acquisitions made by companies like Gilead (Kite Pharma) and Bristol Myers Squibb (Celgene).
• The deal structure, involving a combination of cash offset by debt and potential stock payment, is not uncommon in biotech acquisitions.
• The exclusive processing agreement is a strategic move to secure future revenue, similar to long-term supply agreements seen in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may experience dilution if the remaining consideration is paid in stock.
• Employees of Orgenesis may be involved in the integration of the new technology.
• Customers of Orgenesis may benefit from the expanded capabilities in cell therapy.
• Broaden will become a customer of Orgenesis Maryland LLC for cell therapy processing services.

Next Steps

• Orgenesis will complete the third-party valuation of the acquired assets.
• Orgenesis will integrate the acquired technology into its operations.
• Orgenesis will begin providing cell therapy processing services to Broaden through Orgenesis Maryland LLC.

Key Dates

Keywords

CAR-T, RACE CAR-T, Cell Therapy, Asset Acquisition, Intellectual Property, Biotechnology, Orgenesis, Broaden Bioscience, Technology Transfer, Healthcare